MediWound to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016 at 8:30 a.m. Eastern Time
November 04 2016 - 8:00AM
MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, today announces that the Company
will release financial results for the three and nine months ended
September 30, 2016, at 7:00 a.m. Eastern time on November 14, 2016.
Following the release, MediWound's management
will host a conference call for the investment community beginning
at 8:30 a.m. ET on Monday, November 14, 2016, to discuss the
financial results and to answer questions.
Shareholders and other interested parties may
participate in the conference call by dialing (877) 602-7189
(domestic) or (678) 894-3057 (international) and entering passcode
90184006. The call also will be broadcast live on the Internet on
the Company’s website at www.mediwound.com.
A replay of the call will be accessible two
hours after its completion through November 21, 2016 by dialing
(855) 859-2056 (domestic) or (404) 537-3406 (international) and
entering passcode 90184006. The call will also be archived on the
Company website for 90 days at www.mediwound.com.
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid®, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in Europe
Israel and Argentina. NexoBrid represents a new paradigm in
burn care management, and clinical trials have demonstrated, with
statistical significance, its ability to non-surgically and rapidly
remove the eschar earlier and without harming viable tissue.
MediWound's second innovative product,
EscharEx®, is a topical biological drug being developed for
debridement of chronic and other hard-to-heal wounds and is
complementary to the large number of existing wound healing
products, which require a clean wound bed in order to heal the
wound. EscharEx contains the same proteolytic enzyme technology as
NexoBrid, and benefits from the wealth of existing development data
on NexoBrid. In two Phase 2 studies, EscharEx demonstrated
safety and efficacy in the debridement of chronic and other
hard-to-heal wounds, within a few daily applications.
For more information, please visit
www.mediwound.com.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes
forward-looking statements within the meaning of Section 27A of the
U.S. Securities Act of 1933, as amended, Section 21E of the US
Securities Exchange Act of 1934, as amended, and the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are statements that are not
historical facts, such as statements regarding assumptions and
results related to the regulatory authorizations and launch
dates. In some cases, you can identify forward-looking
statements by terminology such as “believe,” “may,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “expect,”
“predict,” “potential,” or the negative of these terms or other
similar expressions. Forward-looking statements are based on
MediWound’s current knowledge and its present beliefs and
expectations regarding possible future events and are subject to
risks, uncertainties and assumptions. Actual results and the timing
of events could differ materially from those anticipated in these
forward-looking statements as a result of several factors. In
particular, you should consider the risks discussed under the
heading “Risk Factors” in our annual report on Form 20-F for the
year ended December 31, 2015 and information contained in other
documents filed with or furnished to the Securities and Exchange
Commission. You should not rely upon forward-looking statements as
predictions of future events. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or will occur. The
forward-looking statements made herein speak only as of the date of
this announcement and MediWound undertakes no obligation to update
publicly such forward-looking statements to reflect subsequent
events or circumstances, except as otherwise required by law.
Contacts: |
|
Anne Marie Fields |
Sharon Malka |
|
Senior Vice President |
Chief Financial and Operations Officer |
|
LHA |
MediWound |
|
212-838-3777 |
ir@mediwound.co.il |
|
afields@lhai.com
|
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Sep 2023 to Sep 2024